Pfizer vs. J&J: Antithesis to Synthesis
Executive SummaryThe two polar opposites of pharmaceutical strategy--Pfizer with its primary-care, highly centrallized approach and J&J with its niches and decentralization--are testing the limits of their models' capabilities. But these two antitheses are now beginning to move towards a synthesis.
You may also be interested in...
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.